Outcome based schemes are more common than you think

BMJ (Online)

Volumn 341, Issue 7763, 2010, Pages 61-

  Messori, Andrea ^a  

^a Area Vasta Centro   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; DASATINIB; NILOTINIB; PAGAPTANIB; RANIBIZUMAB; SORAFENIB; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; ITALY; KIDNEY CARCINOMA; LETTER; LIVER CARCINOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT OUTCOME; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE DELIVERY; NOTE;

COST-BENEFIT ANALYSIS; HEALTH SERVICES ACCESSIBILITY; HUMANS; ITALY;

EID: 77954677339     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c3588     Document Type: Letter

References (2)

1. Raftery J. Multiple sclerosis risk sharing scheme: a costly failure. BMJ 2010;340:c1672. (3 June.)[Free Full Text]
2. Lucioni C, Mazzi SF, Polcaro F. Il risk sharing come applicazione del value based pricing. PharmacoEconomics - Italian Research Articles 2010;12 (2):71-80.